Product portfolio

The Company's primary focus will be the commercial development of novel cardiovascular-directed growth factor therapeutics for interventional cardiology applications based on the product portfolio acquired by Cardium from Schering. The DNA-based therapeutic products in our portfolio include: (1) Generx (mdFGF-4), our lead product candidate, which has advanced to Phase 2b/3 clinical studies and has been safely administered to 450 patients in the United States, as well as in Europe, Canada and South America. Generx is a non-surgical angiogenic therapy designed as a one-time treatment with long-lasting therapeutic benefits for patients with recurrent angina due to coronary disease; and (2) Corgentin, a pre-clinical product candidate. Corgentin is a next-generation therapeutic using myocardial-derived insulin-like Growth Factor-I (mdIGF-I) and is being designed as a one-time cardiomyocyte-directed treatment to promote the repair and restoration of damaged cardiomyocytes and enhance cardiac function following a heart attack (acute myocardial infarction) through the beneficial cardiac effects of prolonged IGF-I protein expression.

In addition, Cardium secured the rights to Genvascor, a pre-clinical, DNA-based, endothelial nitric oxide synthase (eNOS) therapeutic that is being designed to induce production of nitric oxide directed at mediating the effects of multiple growth factors to enhance neovascularization and increased blood flow for the treatment of patients with critical limb ischemia due to advanced peripheral arterial occlusive disease. We may elect to develop Genvascor alone or in collaboration with a development partner, or seek to externalize this opportunity.